Clinical Trial
Study Details
Outcomes
Use biospecimens procured from patients with cardiac amyloidosis to identify diagnostic surrogate biomarkers using discovery proteomics. The serum levels will be compared between confirmed ATTR and non-ATTR heart failure patients and a diagnostic threshold will be established.
Study Overview
Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by cardiac amyloidosis and therapeutic interventions.
This is a prospective study enrolling patients referred for or undergoing cardiac amyloidosis or cardiovascular treatment at the University of Kentucky. The study aims to facilitate the discovery of novel diagnostic biomarkers and therapeutic targets and improve the pathophysiological understanding of cardiac amyloidosis.
Contacts and Locations
University of Kentucky
Lexington, KY 40536
United States
Study Contact
Participation Criteria
Inclusion Criteria:
* All patients undergoing treatment for cardiac amyloidosis or receiving a right heart catheterization who are at least 18 years of age.
Exclusion Criteria:
* Patients without a cardiovascular or amyloidosis diagnosis, under 18 years of age.
All patients referred for or undergoing treatment for cardiac amyloidosis or receiving a right heart catheterization who are at least 18 years of age.